Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy in anaplastic thyroid cancer.

Literature DB >> 32269728

Immunotherapy in anaplastic thyroid cancer.

Maoguang Ma¹, Bo Lin¹, Mingdian Wang², Xiaoli Liang¹, Lei Su³, Okenwa Okose^4,5, Weiming Lv¹, Jie Li^1,5.

Abstract

Anaplastic thyroid cancer (ATC) is one of the worst human malignancies, with an associated median survival of only 5 months. It is resistant to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression. Cancer immunotherapy has emerged over the past few decades as a transformative approach to treating a wide variety of cancers. However, immunotherapy for ATC is still in the experimental stage. This review will cover several strategies of immunotherapy and discuss the possible application of these strategies in the treatment of ATC (such as targeted therapy for tumor-associated macrophages, cancer vaccines, adoptive immunotherapy, monoclonal antibodies and immune checkpoint blockade) with the hope of improving the prognosis of ATC in the future. AJTR

Entities: Chemical Disease Species

Keywords: Immunotherapy; anaplastic thyroid cancer; immune checkpoint blockade; oncolytic virus and neoantigens; tumor-associated macrophages

Year: 2020 PMID： 32269728 PMCID： PMC7137046

Source DB: PubMed Journal: Am J Transl Res ISSN： 1943-8141 Impact factor: 4.060

110 in total

1. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors: Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal: N Engl J Med Date: 2014-11-19 Impact factor: 91.245

2. The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.

Authors: Sayantan Banerjee; Kuntal Halder; Sweta Ghosh; Anamika Bose; Subrata Majumdar
Journal: Oncoimmunology Date: 2015-01-30 Impact factor: 8.110

Review 3. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

Authors: Kalijn F Bol; Gerty Schreibelt; Winald R Gerritsen; I Jolanda M de Vries; Carl G Figdor
Journal: Clin Cancer Res Date: 2016-04-15 Impact factor: 12.531

Review 4. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.

Authors: Chandrakanth Are; Ashok R Shaha
Journal: Ann Surg Oncol Date: 2006-02-15 Impact factor: 5.344

Review 5. Anti-tumour strategies aiming to target tumour-associated macrophages.

Authors: Xiaoqiang Tang; Chunfen Mo; Yongsheng Wang; Dandan Wei; Hengyi Xiao
Journal: Immunology Date: 2013-02 Impact factor: 7.397

6. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.

Authors: Bernard Caillou; Monique Talbot; Urbain Weyemi; Catherine Pioche-Durieu; Abir Al Ghuzlan; Jean Michel Bidart; Salem Chouaib; Martin Schlumberger; Corinne Dupuy
Journal: PLoS One Date: 2011-07-21 Impact factor: 3.240

Review 7. Oncolytic virotherapy.

Authors: Stephen J Russell; Kah-Whye Peng; John C Bell
Journal: Nat Biotechnol Date: 2012-07-10 Impact factor: 54.908

Review 8. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

Authors: Michael A Cannarile; Martin Weisser; Wolfgang Jacob; Anna-Maria Jegg; Carola H Ries; Dominik Rüttinger
Journal: J Immunother Cancer Date: 2017-07-18 Impact factor: 13.751

9. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.

Authors: Daniel L Suzman; Sundeep Agrawal; Yang-Min Ning; V Ellen Maher; Laura L Fernandes; Stella Karuri; Shenghui Tang; Rajeshwari Sridhara; Jason Schroeder; Kirsten B Goldberg; Amna Ibrahim; Amy E McKee; Richard Pazdur; Julia A Beaver
Journal: Oncologist Date: 2018-12-12

10. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.

Authors: Eran Brauner; Viswanath Gunda; Pierre Vanden Borre; David Zurakowski; Yon Seon Kim; Kate Virginia Dennett; Salma Amin; Gordon James Freeman; Sareh Parangi
Journal: Oncotarget Date: 2016-03-29

9 in total

1. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.

Authors: Luca Hegedűs; Dominika Rittler; Tamás Garay; Paul Stockhammer; Ildikó Kovács; Balázs Döme; Sarah Theurer; Thomas Hager; Thomas Herold; Stavros Kalbourtzis; Agnes Bankfalvi; Kurt W Schmid; Dagmar Führer; Clemens Aigner; Balázs Hegedűs
Journal: Pathol Oncol Res Date: 2020-06-26 Impact factor: 3.201

2. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.

Authors: Inmaculada Isorna; Francisco Esteban; Juan Solanellas; Rafael Coveñas; Miguel Muñoz
Journal: Eur J Histochem Date: 2020-04-28 Impact factor: 3.188

Review 3. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors: María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal: Int J Mol Sci Date: 2020-07-13 Impact factor: 5.923

4. Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.

Authors: Shichen Xu; Xian Cheng; Jing Wu; Yunping Wang; Xiaowen Wang; Liying Wu; Huixin Yu; Jiandong Bao; Li Zhang
Journal: J Mol Cell Biol Date: 2022-01-21 Impact factor: 6.216

5. Bibliometric Insights in Advances of Anaplastic Thyroid Cancer: Research Landscapes, Turning Points, and Global Trends.

Authors: Hanyu Wang; Yuxin Yu; Kang Wang; Hui Sun
Journal: Front Oncol Date: 2021-11-24 Impact factor: 6.244

Review 6. The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options.

Authors: Maria Linda Rocha; Kurt Werner Schmid; Piotr Czapiewski
Journal: Contemp Oncol (Pozn) Date: 2021-10-14